| Project/Area Number |
07671393
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
HIZUTA Akio Okayama Univ.Med.Sch., First Dept.Surg., Assistant Prof., 医学部・附属病院, 講師 (60199007)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YASUDA Tatsuji Okayama Univ.Med.Sch., Dept.Cell Chem., 医学部, 教授 (30092357)
FUJIWARA Toshiyoshi Okayama Univ.Med.Sch., First Dept.Surg., 医学部・附属病院, 医員
|
|---|
| Project Period (FY) |
1995 – 1996
|
| Project Status |
Completed (Fiscal Year 1996)
|
| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1996: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1995: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | p53 / Gene Therapy / Colon Cancer / Cisplatin / アデノウイルスベクター / ウイルスベクター |
|---|
| Research Abstract |
The alteration of wild-type p53 gene by mutations, deletions, or rearrangements is a major factor in the development of human colon cancer. Recent studies have demonstrated that p53 might be an essential component of the cytotoxic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We examined the antitumor effect of adenovirus-mediated wild-type p53 gene transfer in combination with a chemotherapeutic drug on human colon cancer cell line WiDr, which has a homozygous mutated p53 gene. The treatment with a chemotherapeutic drug, cisplatin, following the infection of a replication-deficient, recombinant adenoviral vector expressing wt-p53 (termed AdCMV p53) significantly suppressed the growth of WiDr cells compared to any single treatments. To evaluate the in vivo efficacy of AdCMV p53 and cisplatin given in a sequential combination, WiDr cells were subcutaneously inoculated in nu/nu mice, and after 3 days AdCMV p53 was subcutaneously injected into the area where tumor cells were implanted followed by intraperitoneal administration of cisplatin. Analysis of initial growth inhibition at 21 days demonstrated a profound, therapeutic cooperativity, although AdCMV p53 alone or cisplatin alone showed a modest slowing of the tumor growth. These results suggest that the gene therapy using wt-p53-expressing a denovirus in combination with a chemotherapeutic DNA-damaging drug is a useful strategy for human colon cancer therapy.
|
